Melatonin as a potential treatment for septic cardiomyopathy.

Autor: Taha AM; Faculty of Medicine, Fayoum University, Fayoum, Egypt; Medical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA., Mahmoud AM; Faculty of Medicine, Menoufia University, Menoufia, Egypt., Ghonaim MM; Faculty of Medicine, Menoufia University, Menoufia, Egypt., Kamran A; Bachelor of Medicine, Bachelor of Surgery, Karachi Medical and Dental College, Karachi, Pakistan., AlSamhori JF; Faculty of Medicine, University of Jordan, Amman, Jordan., AlBarakat MM; Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan., Shrestha AB; Department of Internal Medicine, M Abdur Rahim Medical College, Dinajpur, Bangladesh. Electronic address: Abigan17@gmail.com., Jaiswal V; Larkin Community Hospital, South Miami, Fl, USA., Reiter RJ; Department of Cell Systems and Anatomy, UT Health San Antonio, San Antonio, TX, USA.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Oct; Vol. 166, pp. 115305. Date of Electronic Publication: 2023 Aug 22.
DOI: 10.1016/j.biopha.2023.115305
Abstrakt: Septic cardiomyopathy (SCM) is a common complication of sepsis contributing to high mortality rates. Its pathophysiology involves complex factors, including inflammatory cytokines, mitochondrial dysfunction, oxidative stress, and immune dysregulation. Despite extensive research, no effective pharmacological agent has been established for sepsis-induced cardiomyopathy. Melatonin, a hormone with diverse functions in the body, has emerged as a potential agent for SCM through its anti-oxidant, anti-inflammatory, anti-apoptotic, and cardioprotective roles. Through various molecular levels of its mechanism of action, it counterattacks the adverse event of sepsis. Experimental studies have mentioned that melatonin protects against many cardiovascular diseases and exerts preventive effects on SCM. Moreover, melatonin has been investigated in combination with other drugs such as antibiotics, resveratrol, and anti-oxidants showing synergistic effects in reducing inflammation, anti-oxidant, and improving cardiac function. While preclinical studies have demonstrated positive results, clinical trials are required to establish the optimal dosage, route of administration, and treatment duration for melatonin in SCM. Its safety profile, low toxicity, and natural occurrence in the human body provide a favorable basis for its clinical use. This review aims to provide an overview of the current evidence of the use of melatonin in sepsis-induced cardiomyopathy (SICM). Melatonin appears to be promising as a possible treatment for sepsis-induced cardiomyopathy and demands further investigation.
Competing Interests: Declaration of Competing Interest All the authors declare no conflict of interest.
(Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: